Vaccines reduce the incidence of corona virus hospitalization, New UK studies show

LONDON – Preliminary studies of the UK’s mass vaccination program showed strong signs of activation of the corona virus vaccine on Monday, providing one of the clearest indications that vaccines are drastically reducing rates. Hospitalization due to COVID-19 and reduced viral transmission.

According to British studies, a single dose Astrogenogen vaccine Or something made by Pfizer may prevent you from being admitted to a corona virus-related hospital, although it is too quick to give an accurate estimate of its effect, the researchers said.

AstraZeneca’s vaccine results, which first appeared outside of clinical trials, provide a strong signal for the vaccine’s effectiveness, which most parts of the world believe will end the epidemic.

Other studies of Pfizer vaccine have promoted new evidence that an injection can reduce the spread of the virus, showing that it prevents not only the symptomatic occurrence of COVID-19 but also asymptomatic infections.

These findings strengthened and surpassed Israel’s previous conclusions that the vaccine developed by Pfizer and Bioentech provided significant protection against the virus in real-world settings, not just in clinical trials conducted last year. No other major nation has vaccinated people as quickly as the United Kingdom, the first country in the world to license and use both the Pfizer vaccine and AstraZeneca and the University of Oxford.

Studies published on Monday showed that both vaccines – Pfizer injection and Astrogeneneka – are effective against the highly contagious variant of the corona virus that is prevalent in the UK and around the world.

Aziz Sheikh, a professor at the University of Edinburgh who took part in the study, told a news conference on Monday.

The UK has delayed the administration of the second dose of the Pfizer and AstraZeneca vaccine for the first three months, and has chosen to provide some protection to more people with one injection.

Transactions to that conclusion were not entirely clear in a study released Monday, but government scientists said reducing the rates of hospital admissions justifies that strategy.

But the findings also show that people were better protected from the corona virus after the second dose. They gave mixed answers to the question of how long a high dose of protection from a single dose would last.

“We now need to understand how long this protection lasts for a single dose of the vaccine,” said Arne Akbar, a professor at the University of London and head of the British Society for Immunology.

One new study looked at about 19,000 health workers in the UK who have been vaccinated against pfizer. Scientists were able to monitor whether the subjects were infected or not: they were periodically tested for the virus, whether they showed symptoms or not, which allowed scientists to detect asymptomatic events.

Until now, clinical trials have only seen multiple symptomatic infections.

That study shows that a single dose of Pfizer vaccine reduced the risk of infection by about 70 percent. According to scientists, coverage increased to 85 percent after two doses of the vaccine, although they warned that a small number of cases would make it difficult to obtain accurate estimates.

The Pfizer vaccine also seemed to be effective in the elderly, they were not well mentioned in clinical trials and did not always produce strong responses to vaccines. Other research has shown that a single dose is 57 percent effective in preventing the occurrence of COVID-19 in people over the age of 80 in the UK. Safety increased to 88 percent after the second dose.

See also  In the UK, a start-up is testing a rocket engine with recyclable plastic fuel

Elderly people who became ill within the next two weeks or so after receiving the first dose of the vaccine had significantly fewer contraindications to hospitalization or death. It says the Pfizer vaccine has mitigated the impact of infections, although it has not completely stopped them.

However, some who were vaccinated were hospitalized or died of the virus, which is thought to be a reminder that “safety is not complete,” said Mary Ramsay, immunization chief for the UK Public Health Organization.

A Scottish study looked at Pfizer and AstraZeneca levels. The results of the Astrogeneca vaccine were very low because the approval for its use in the UK was later, and it was only implemented in early January.

The researchers admitted about 8,000 corona virus-related patients to the hospital and studied how the risk of hospitalization varies between vaccinated and non-vaccinated individuals.

Because the number of people being treated in hospitals was so small, they could only generate approximate statistics for the effectiveness of vaccines and could not compare the sizes of different organizations, the researchers said.

But 28 to 34 days after the first injection, when it appeared to be at or near its maximum effectiveness, the Astrogeneka vaccine reduced the risk of hospital admission for COVID-19 by about 94 percent. During the same period, the Pfizer vaccine reduced the risk of hospitalization by about 85 percent. In both cases, the numbers were too small to believe the exact result.

These findings are a definite indication of the effectiveness of the AstraZeneca vaccine, the backbone of vaccination programs in many countries: it is much cheaper to manufacture and, unlike Pfizer and Moderna, can be shipped in ordinary refrigerators that have not yet been used in the UK.

See also  UK DNA study reveals two prehistoric human groups

However, British studies have not been able to resolve the duration of overdose protection from a single dose of the Pfizer or AstraZeneca vaccine.

In Scottish research, the risk of hospitalization decreased from the week people received the first dose, reaching the lowest point between four and five weeks after vaccination. But then it seemed to increase again.

“The safety spike occurs in four weeks, after which it begins to decline,” said Simon Clark, a professor of cell microbiology at the University of Reading who was not involved in the study.

In the UK, there is no evidence that the level of protection decreases after one month. The scientists said they needed more evidence to definitively establish how quickly the safety of giving a single dose after a month could be reduced.

The AstraZeneca vaccine was met with suspicion from some parts of Europe because many countries chose not to give it to the elderly, claiming that there was no data on clinical trials in that population.

Scottish research has not been able to provide accurate statistics on the effectiveness of that vaccine in the elderly. But the vaccination program significantly reduced hospital admissions for people over the age of 80, and many older people received the astrogenic vaccine.

Benjamin Mல்லller was the UK correspondent for The New York Times. He has been a reporter on police and law enforcement issues in the metro division since 2014. en Benchmர்ller

You May Also Like

About the Author: Morton Obrien

"Reader. Infuriatingly humble travel enthusiast. Extreme food scholar. Writer. Communicator."

Leave a Reply

Your email address will not be published. Required fields are marked *